GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (NAS:ANIP) » Definitions » Shiller PE Ratio

ANI Pharmaceuticals (ANI Pharmaceuticals) Shiller PE Ratio : (As of May. 19, 2024)


View and export this data going back to 1999. Start your Free Trial

What is ANI Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ANI Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for ANI Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Shiller PE Ratio Chart

ANI Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ANI Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ANI Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANI Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Shiller PE Ratio falls into.



ANI Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ANI Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, ANI Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.82/131.7762*131.7762
=0.820

Current CPI (Mar. 2024) = 131.7762.

ANI Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.210 100.560 -0.275
201409 0.590 100.428 0.774
201412 1.820 99.070 2.421
201503 0.380 99.621 0.503
201506 0.310 100.684 0.406
201509 0.390 100.392 0.512
201512 0.250 99.792 0.330
201603 0.120 100.470 0.157
201606 0.100 101.688 0.130
201609 0.220 101.861 0.285
201612 -0.100 101.863 -0.129
201703 0.100 102.862 0.128
201706 0.230 103.349 0.293
201709 0.400 104.136 0.506
201712 -0.830 104.011 -1.052
201803 0.190 105.290 0.238
201806 0.230 106.317 0.285
201809 0.420 106.507 0.520
201812 0.460 105.998 0.572
201903 0.040 107.251 0.049
201906 0.530 108.070 0.646
201909 0.320 108.329 0.389
201912 -0.410 108.420 -0.498
202003 -0.590 108.902 -0.714
202006 -1.030 108.767 -1.248
202009 0.040 109.815 0.048
202012 -0.300 109.897 -0.360
202103 0.010 111.754 0.012
202106 -1.170 114.631 -1.345
202109 -0.370 115.734 -0.421
202112 -1.720 117.630 -1.927
202203 -1.270 121.301 -1.380
202206 -0.940 125.017 -0.991
202209 -0.550 125.227 -0.579
202212 -0.280 125.222 -0.295
202303 0.060 127.348 0.062
202306 0.290 128.729 0.297
202309 0.450 129.860 0.457
202312 0.020 129.419 0.020
202403 0.820 131.776 0.820

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ANI Pharmaceuticals  (NAS:ANIP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ANI Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ANI Pharmaceuticals (ANI Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Executives
Muthusamy Shanmugam director, officer: HEAD OF R&D, COO-NOVITIUM OPS C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Meredith Cook officer: SR. VP, GENERAL COUNSEL & SEC. C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Krista Davis officer: SVP, CHIEF HR OFFICER C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Christopher Mutz officer: HEAD OF RARE DISEASE C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Chad Gassert officer: SVP - CORP. DEV. & STRATEGY C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Ori Gutwerg officer: SVP, GENERICS C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
James G. Marken officer: Vice President, Operations 210 MAIN STREET WEST, C/O BIOSANTE PHARMACEUTICALS, INC., BAUDETTE MN 56623
Matthew J Leonard director 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Meridian Venture Partners Ii Lp 10 percent owner
Nikhil Lalwani director, officer: PRESIDENT & CEO C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Antonio R Pera director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Stephen P. Carey officer: Vice President and CFO C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Jeanne Thoma director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780